Compare · DXCM vs NVST
DXCM vs NVST
Side-by-side comparison of DexCom Inc. (DXCM) and Envista Holdings Corporation (NVST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NVST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 8.8x NVST ($3.77B).
- Over the past year, DXCM is up 29.2% and NVST is up 14.7% - DXCM leads by 14.5 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 2 for NVST).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Envista Holdings Corporation
- Price
- $86.05-1.93%
- $22.91-2.51%
- Market cap
- $33.10B
- $3.77B
- 1M return
- -2.13%
- -3.27%
- 1Y return
- +29.24%
- +14.70%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2019
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest NVST
- Envista downgraded by Robert W. Baird with a new price target
- Envista Schedules Third Quarter 2026 Earnings Call
- Envista Holdings Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Envista Announces Participation in Baird 2026 Global Healthcare Conference
- Envista upgraded by Analyst with a new price target
- President, Orthodontics Acurio Veronica covered exercise/tax liability with 7,710 shares, decreasing direct ownership by 14% to 48,806 units (SEC Form 4) (tax withholding)
- President, Diagnostics Befidi Robert covered exercise/tax liability with 5,147 shares, decreasing direct ownership by 10% to 45,785 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Hammes Eric D. covered exercise/tax liability with 10,885 shares, decreasing direct ownership by 10% to 99,913 units (SEC Form 4) (tax liability)
- President, Nobel Biocare Nilsson Stefan covered exercise/tax liability with 804 shares, decreasing direct ownership by 1% to 61,560 units (SEC Form 4) (withholding tax)
- SVP, Strategy & Bus. Dev. Reis Mischa sold $220,000 worth of shares (8,000 units at $27.50) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 27,321 units (SEC Form 4)